EyeYon Medical

Company Overview

Snapshot

Founded in January 2010 by Nahum Ferera, Arie Marcovich, and Ofer Daphna, EyeYon Medical operates with 11–50 employees. The company has raised $36.14 million across 4 funding rounds from 12 investors. In March 2021, EyeYon Medical raised $25 million for corneal implants, with CR-CP Life Science Fund leading the round.

Business overview

EyeYon Medical is a startup specializing in the development of medical ophthalmic devices designed to address complications arising from various corneal diseases, including corneal edema. The company's core technology includes an artificial endothelial layer called EndoArt, a synthetic implant for treating chronic corneal edema secondary to endothelial dysfunction. EyeYon Medical also developed Hyper CL, an FDA-approved therapeutic contact lens. The company serves the ophthalmic market, providing solutions for patients and healthcare providers in clinics and hospitals, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In February 2025, EyeYon Medical announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co. This strategic move signals the company's commitment to global market penetration and indicates a significant growth opportunity in the large Chinese healthcare market for its ophthalmic innovations.

Company Intelligence Q&A

What is EyeYon Medical's flagship product?

EyeYon Medical's flagship product is EndoArt, an artificial endothelial layer designed as a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction.

When did EyeYon Medical receive FDA Breakthrough Device Designation for EndoArt?

In February 2020, EyeYon Medical received Breakthrough Device Designation from the FDA for its EndoArt product.

What was a significant funding event for EyeYon Medical in 2021?

In March 2021, EyeYon Medical raised $25 million for its corneal implants. CR-CP Life Science Fund led this funding round.

Has EyeYon Medical expanded its market presence recently?

Yes, in February 2025, EyeYon Medical expanded into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.

When was the Hyper CL therapeutic contact lens approved by the FDA?

In September 2016, the FDA approved EyeYon Medical's Hyper CL therapeutic contact lens for a variety of corneal conditions.